Geno Germano - Pfizer President

PFE Stock  EUR 25.60  0.15  0.59%   

President

Mr. Geno J. Germano is Group President Global Innovative Pharma Business of Pfizer Inc. since January 2014. He was President and General Manager Pfizer Specialty Care and Oncology from December 2010 until December 2013. President and General Manager Specialty Care from October 2009 until December 2010. President U.S. Pharmaceuticals and Womens Health Care Unit Wyeth Pharmaceuticals from 2008 through October 2009. President and General Manager U.S. Pharmaceutical Business Unit Wyeth Pharmaceuticals from 2007 through 2008. Member of the Board of Trustees for Albany College of Pharmacy and Health Sciences and Member of the Board of Directors of BIO Biotechnology Industry Organization. Director of Zoetis Inc. from July 2012 until June 2013. since 2014.
Age 53
Tenure 10 years
Phone212 733 2323
Webhttps://www.pfizer.com

Pfizer Management Efficiency

The company has return on total asset (ROA) of 0.1287 % which means that it generated a profit of $0.1287 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.3622 %, meaning that it generated $0.3622 on every $100 dollars invested by stockholders. Pfizer's management efficiency ratios could be used to measure how well Pfizer manages its routine affairs as well as how well it operates its assets and liabilities.
The company has accumulated 34.76 B in total debt with debt to equity ratio (D/E) of 78.8, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Pfizer Inc has a current ratio of 1.51, which is within standard range for the sector. Debt can assist Pfizer until it has trouble settling it off, either with new capital or with free cash flow. So, Pfizer's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Pfizer Inc sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Pfizer to invest in growth at high rates of return. When we think about Pfizer's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

PRESIDENT Age

Barton PetersonEli Lilly And
57
Rob DorranSuperior Plus Corp
N/A
Maria CroweEli Lilly And
55
Jeffrey SimmonsEli Lilly And
48
Michael FarrellSuperior Plus Corp
N/A
Michael HarringtonEli Lilly And
53
Gavin HarveyNorAm Drilling AS
59
Jimmy CastroNorAm Drilling AS
50
Alfonso ZuluetaEli Lilly And
53
Andrew PeytonSuperior Plus Corp
55
David EldersveldNorAm Drilling AS
N/A
Melissa BarnesEli Lilly And
47
Leigh PuseyEli Lilly And
60
Lawrence WertNorAm Drilling AS
61
Fionnuala WalshEli Lilly And
56
Gregory McCamusSuperior Plus Corp
N/A
Joshua SmileyEli Lilly And
47
Jay BachmanSuperior Plus Corp
N/A
David RicksEli Lilly And
55
Shawn VammenSuperior Plus Corp
N/A
Enrique ConternoEli Lilly And
49
Pfizer Inc. develops, manufactures, and sells healthcare products worldwide. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York. PFIZER INC operates under Drug Manufacturers - Major classification in Germany and is traded on Frankfurt Stock Exchange. It employs 92400 people. Pfizer Inc (PFE) is traded on Frankfurt Exchange in Germany and employs 83,000 people.

Management Performance

Pfizer Inc Leadership Team

Elected by the shareholders, the Pfizer's board of directors comprises two types of representatives: Pfizer inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pfizer. The board's role is to monitor Pfizer's management team and ensure that shareholders' interests are well served. Pfizer's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pfizer's outside directors are responsible for providing unbiased perspectives on the board's policies.
John Young, Group President - Global Established Pharma Business
Jennifer Damico, Controller VP
Frank DAmelio, CFO, Executive Vice President - Business Operations
Douglas Lankler, Executive Vice President General Counsel
Dawn Rogers, Chief Human Resource Officer, Executive Vice President
Helen Hobbs, Independent Director
Shantanu Narayen, Director
James Smith, Director
Christopher CFA, VP Officer
Dennis Ausiello, Independent Director
Mikael Dolsten, President - Worldwide Research and Development
Frances Fergusson, Independent Director
Stephen Sanger, Independent Director
Lidia Fonseca, Executive Vice President CTO and Digital Officer
Wyllie Cornwell, Independent Director
Suzanne Johnson, Independent Director
David Denton, Chief VP
Alexander Mackenzie, Executive Vice President Chief Development Officer
DVM DVM, Chairman CEO
Geno Germano, Group President - Global Innovative Pharma Business
Laurie Olson, Executive Vice President - Strategy, Portfolio and Commercial Operations
Sally Susman, Executive Vice President - Corporate Affairs
Anthony Maddaluna, Executive Vice President and Presidentident - Pfizer Global Supply
Freda LewisHall, Executive Vice President Chief Medical Officer
Rady Johnson, Executive Vice President Chief Compliance and Risk Officer
Mikael MD, Dev Research
Dan Littman, Director
Ian Read, Chairman of the Board, CEO
James Kilts, Independent Director
Don Cornwell, Independent Director
Charles Hill, Executive Vice President - Worldwide Human Resources
Joseph Echevarria, Director
Albert Bourla, Group President - Vaccines, Oncology and Consumer Healthcare Business
Kirsten LundJurgensen, Executive Vice President and Presidentident - Pfizer Global Supply
Angela Hwang, Group President - Pfizer Essential Health
Scott Gottlieb, Director
Ronald Blaylock, Independent Director
Kathrin Jansen, Senior Vice President - Vaccine Research & Development
Michael Goettler, Group President - Pfizer Upjohn

Pfizer Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pfizer a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Pfizer in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Pfizer's short interest history, or implied volatility extrapolated from Pfizer options trading.

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Pfizer Inc using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
When determining whether Pfizer Inc is a strong investment it is important to analyze Pfizer's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pfizer's future performance. For an informed investment choice regarding Pfizer Stock, refer to the following important reports:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pfizer Inc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Complementary Tools for Pfizer Stock analysis

When running Pfizer's price analysis, check to measure Pfizer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pfizer is operating at the current time. Most of Pfizer's value examination focuses on studying past and present price action to predict the probability of Pfizer's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pfizer's price. Additionally, you may evaluate how the addition of Pfizer to your portfolios can decrease your overall portfolio volatility.
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Fundamental Analysis
View fundamental data based on most recent published financial statements
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Equity Valuation
Check real value of public entities based on technical and fundamental data
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Funds Screener
Find actively-traded funds from around the world traded on over 30 global exchanges
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Please note, there is a significant difference between Pfizer's value and its price as these two are different measures arrived at by different means. Investors typically determine if Pfizer is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pfizer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.